abstract |
The present invention relates to a series of novel analogs of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as agonists or antagonists of the GIP receptor for the treatment of conditions mediated by the GIP receptor. , such as non-insulin dependent diabetes mellitus and obesity. |